Provided by Tiger Trade Technology Pte. Ltd.

Rapport Therapeutics, Inc.

49.33
+1.092.26%
Pre-market: 49.990.6600+1.34%09:28 EDT
Volume:365.42K
Turnover:18.04M
Market Cap:2.37B
PE:-16.16
High:50.34
Open:48.16
Low:47.44
Close:48.24
52wk High:50.34
52wk Low:14.11
Shares:47.98M
Float Shares:30.39M
Volume Ratio:1.64
T/O Rate:1.20%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.0525
EPS(LYR):-2.8633
ROE:-39.96%
ROA:-25.78%
PB:5.60
PE(LYR):-17.23

Loading ...

Rapport Therapeutics initiated with an Outperform at William Blair

TIPRANKS
·
Jul 28

Analysts Offer Insights on NA Companies: CAMP4 Therapeutics Corporation (CAMP), Fiserv (FISV) and Rapport Therapeutics, Inc. (RAPP)

TIPRANKS
·
Jul 28

Goldman Sachs Sticks to Their Buy Rating for Rapport Therapeutics, Inc. (RAPP)

TIPRANKS
·
Jul 22

Analysts Offer Insights on NA Companies: Solv Energy (Nasdaq: MWH), Rapport Therapeutics, Inc. (RAPP) and Volvo Car AB Class B (OtherVLVOF)

TIPRANKS
·
Jul 18

Rapport Therapeutics Price Target Maintained with a $65.00/share by BTIG

Dow Jones
·
Jul 16

Rapport Therapeutics CEO Abraham Ceesay Sells 8,210 Common Shares Worth $328,018

Reuters
·
Jul 16

Rapport Therapeutics management to meet with Citizens

TIPRANKS
·
Jul 16

4x P B For Rapport Therapeutics (RAPP) After Russell Index Additions Looks Pricey

Simply Wall St.
·
Jul 06

Rapport Therapeutics CEO Abraham Ceesay Disposes of Common Shares Worth $327,031.55

Reuters
·
Jul 02

Does Truist’s New RAPP Coverage Subtly Reframe Rapport Therapeutics’ Long-Term Credibility Story (RAPP)?

Simply Wall St.
·
Jun 26

1 Reason Rapport Therapeutics (RAPP) Looks Pricey Following Truist Buy Coverage

Simply Wall St.
·
Jun 25

Rapport Therapeutics Initiated at Outperform by Leerink Partners

Dow Jones
·
Jun 25

Leerink Partners Initiates Rapport Therapeutics at Outperform With $52 Price Target

MT Newswires Live
·
Jun 24

Rapport Therapeutics initiated with an Outperform at Leerink

TIPRANKS
·
Jun 24

Rapport Therapeutics Inc : Leerink Partners Initiates Coverage with Outperform Rating; Price Target $52

THOMSON REUTERS
·
Jun 24

Rapport Therapeutics Holds 2026 Annual Shareholder Meeting

TIPRANKS
·
Jun 11

Rapport Therapeutics shareholders elected Class II directors at annual meeting

Reuters
·
Jun 11

Rapport Therapeutics (RAPP) Is Down 9% After Strong RAP-219 Data Outshines Rival Trial - Has The Bull Case Changed?

Simply Wall St.
·
Jun 06

RAPP Advances RAP-219 Into Phase 3, Raising the Stakes in Focal Epilepsy

TIPRANKS
·
Jun 05

BTIG Reaffirms Their Buy Rating on Rapport Therapeutics, Inc. (RAPP)

TIPRANKS
·
Jun 02